IL17A and psoriasis: Second, the study performed targeted metabolic analysis of LCFA alterations in psoriasis patients receiving pretherapy and posttreatment with anti-IL-17A mAb, which was a unique approach compared to previous metabolic analyses comparing healthy volunteers and psoriasis patients.